Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies
Laurence Lousberg(Centre Hospitalier Chrétien), Guy Jérusalem(Centre Hospitalier Universitaire de Liège), Joëlle Collignon(Centre Hospitalier Universitaire de Liège)
Cited by 40
Related Papers
Triple-negative breast cancer: treatment challenges and solutions
|Breast Cancer Targets and Therapy|2016|382
Cardio-Oncology Services: rationale, organization, and implementation
|European Heart Journal|2018|303
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
|The Lancet Oncology|2019|193
Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis
|JNCI Journal of the National Cancer Institute|2020|102